Nirman Agri Genetics Limited

3rd floor, Samarth House, Opposite Titan World, Mahatma Nagar, Nashik, India, 422005
Contact: 0253-2943101
Email: admin@nirmanagrigen.com Web: www.nirmanagrigen.com
CIN No: U0111OMH2020PLC344089 **GST No**: 27AAHCN1021C1Z3

February 06, 2025

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Symbol – NIRMAN

Sub.: Integrated Filing (Financial) for the Quarter and the Nine Month ended 31st December 2024

Dear Sir / Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-POD/2/CIR/P/2024/185 dated 31st December 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 02nd January 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and the nine months ended 31st December 2024. We request you to kindly take the above on record

Kindly take the same on record and oblige.

Thanking you,
For Nirman Agri Genetics Limited

RIDDHI NITIN AHER
Digitally signed by RIDDHI NITIN AHER
Date: 2025.02.06 16:38:50 +05'30'

Riddhi Nitin Aher
Director
DIN: 09815607

Nirman Agri Genetics Limited

3rd floor, Samarth House, Opposite Titan World, Mahatma Nagar, Nashik, India, 422005

Contact: 0253-2943101

Email: admin@nirmanagrigen.com Web: www.nirmanagrigen.com

CIN No: U0111OMH2020PLC344089 **GST No**: 27AAHCN1021C1Z3

Integrated Filing (Financial) for the quarter and the nine months ended 31st December 2024

Financial Results	Enclosed as Annexure
Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	Not Applicable
Format for disclosing outstanding default on loans and debt securities	Not Applicable
Format for disclosure of related party transactions (applicable only for half yearly filings i.e., 2nd and 4th quarter)	Not Applicable
Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)	Not Applicable

M/s. Devendra C. Belan & Associates
Chartered Accountants

REVIEW REPORT ON STANDALONE UNAUDITED FINANCIAL RESULTS

To

The Board of Directors

Nirman Agri Genetics Limited

1. We have reviewed the Standalone Unaudited Financial Results of Nirman Agri Genetics Limited ("the company") for the quarter and nine months ended December 31, 2024 which are included in the accompanying Statement of Standalone Unaudited Financial Results for the Quarter and nine months ended December 31,2024" (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

M/s. Devendra C. Belan & Associates
FRN No. 126495 W
Nashik
Chartered Accountants

3, First Floor, Gajanan Avenue, New Pandit Colony, Gangapur Road, Nasik - 422 002.
Ph.: 0253-2319640, 2232640 E-mail : dcbelan@gmail.com dcbelan@rediffmail.com

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review of Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

4. A review is limited primarily to inquiries of company personnel and an analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies and has not disclosed the information required) to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Devendra C. Belan & Associates
Chartered Accountants
FRN – 126495W

M/s. Devendra C. Belan & Associates
FRN No. 126495 W
Nashik
Chartered Accountants

CA. Devendra C. Belan
Proprietor
M No. 119372
Date: - 05th February 2025
UDIN: - 25119372BMHTES5668

NIRMAN AGRI GENETICS LIMITED
(Formerly known as Nirman Agri Genetics Private Limited)
Registered Office Address - 3rd Floor, Samarth House, Opp. Titan World, Mahatma Nagar, Nashik 422005
CIN -U01110MH2020PLC344089
UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2024
Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

(Rs.In Lakhs)

	Particulars	Quarter Ended				Nine Months Ended		Year Ended
		31-12-2024	30-09-2024	30-06-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Whether results are audited or unaudited	**Unaudited**	**Unaudited**	**Unaudited**	**Unaudited**	**Unaudited**	**Unaudited**	**Audited**
I	Revenue From Operations	6,107.20	6209.19	5,035.39	1,889.24	17,351.77	4,287.72	6,333.72
II	Other Income	-	-	-	-	-	-	-
								-
III	**Total Income (I+II)**	6,107.20	6,209.19	5,035.39	1,889.24	17,351.77	4,287.72	6,333.72
IV	**Expenses**							
	Cost of Materials Consumed , Cost of Production	5,276.29	5428.39	4,411.46	1473.79	15,116.14	3,312.91	4,933.60
	Purchases of Stock -In-Trade	-	-	-	-	-	-	-
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-	-
	Employee Benefit Expenses	46.45	45.12	40.66	52.08	132.23	111.58	147.75
	Finance Costs	0.54	0.64	0.50	0.61	1.69	1.30	2.03
	Depreciation and Amortization Expenses	35.87	8.79	4.14	5.09	48.81	14.03	31.65
	Other Expenses	62.94	61.11	55.54	42.29	179.60	98.00	124.92
	Total Expenses	5,422.10	5,544.06	4,512.31	1,573.86	15,478.47	3,537.82	5,239.95
V	Profit Before Exceptional and Extraordinary Items and Tax (III-IV)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
VI	Exceptional Items	-	-	-	-	-	-	-
VII	Profit Before Extraordinary Items and Tax (V - VI)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
VIII	Extraordinary Items	-	-	-	-	-	-	-
IX	Profit Before Tax (VII- VIII)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
								`
X	Tax Expense:							
	(1) Current Tax	12.08	23.52	19.54	0.93	55.14	43.38	49.95
	(2) Deferred Tax	-	-	-	-	-	-	3.36
XI	**Profit / (Loss) For The Period From Continuing Operations (VII-VIII)**	673.02	641.61	503.54	314.45	1,818.16	706.52	1,040.47
XII	**Profit / (Loss) For The Period From Discontinuing Operations**	-	-	-	-	-	-	-
XIII	**Tax Expense of Discontinuing Operations**	-	-	-	-	-	-	-
XIV	**Profit / (Loss) For The Period From Discontinuing Operations (After Tax) (XII-XIII)**	-	-	-	-	-	-	-
XV	**Profit (Loss) For The Period (XI+XIV)**	673.02	641.61	503.54	314.45	1,818.16	706.52	1,040.47
XVI	**Deatails of paid up Share Capital**							
	Paid up Share Capital	800.97	800.97	596.08	596.08	800.97	596.08	596.08
	Face Value of Equity Share Capital(Per Share) (in Rs.)	10.00	10.00	10.00	10.00	10.00	10.00	10.00
XVII	**Earnings Per Equity Share (EPS)**							
	(i) Basic	8.40	8.01	8.45	5.28	22.70	11.85	17.46
	(ii) Diluted							

Notes

1.The Financial Results have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors in its meeting held on 5th February 2025.

2.The figures for the Previous period/ Quarter & Nine month ended have been rearranged/re-grouped wherever necessary, to confirm with the figures for the current year/Quarter & Nine Month ended.

3. The Financial results are prepared in accordance with the Accounting Standard ("AS") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules.

4. The entire operation of the Company relate to only one segment. Hence,Ind AS-108 is not applicable. Thus, no separate disclosure for segment reporting is made.

For & on behalf of the Board of Directors
Nirman Agri Genetics Limited

Pranav Kailas Bagal
Digitally signed by Pranav Kailas Bagal
Date: 2025.02.05 13:25:32 +05'30'

Place - Nashik
Date - 05/02/2025

Pranav Kailas Bagal
Managing Director
DIN - 08839908